Host Hotels & Resorts Inc. Common Stock vs Merck & Co., Inc. — how do they compare? Host Hotels & Resorts Inc. Common Stock trades at $22.65 (market cap $15.44B), while Merck & Co., Inc. trades at $145.6 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 22.8× Host Hotels & Resorts Inc. Common Stock's market cap, and Host Hotels & Resorts Inc. Common Stock pays the higher dividend (3.55%). Which is the better fit depends on your goals — on Pluang, investors hold Host Hotels & Resorts Inc. Common Stock for 0 Days and Merck & Co., Inc. for 98 Days on average.
| HST | MRK | |
|---|---|---|
Market Cap | $15.44B | $351.28B |
Volume | 6,250,070 | 7,969,665 |
Sector | Real Estate | Health |
52-Week High | $25.54 | $156.43 |
52-Week Low | $15.82 | $82.49 |
Typical Hold Time | 0 Days | 98 Days |
Enterprise Value | $19.13B | $398.04B |
Dividend Yield | 3.55% | 2.39% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $65.01 billion in 2025, and net income reached $18.25 billion. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, with institutional investors increasing stakes.
The outlook for Merck is supported by analyst consensus with a $158.78 price target and 68% buy ratings, but risks include high valuation multiples like a P/E of 113.9 and competitive pressures in the pharma sector. The stock's investment appeal hinges on pipeline execution and integration of acquisitions amid a challenging technical backdrop.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Host Hotels & Resorts is a real estate investment trust that owns luxury and upscale hotel properties. Its portfolio includes hotels operated under major global brands.
Read more on HST →Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →